- NYSE American: IMUC*
- Sector: Healthcare
- Industry: Biotechnology
ImmunoCellular Therapeutics, Ltd., based in Los Angeles, is developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Additional assets, for which the Company is seeking partners, include clinical-stage programs – ICT-107, ICT-121 and ICT-140 – which are patient-specific, dendritic cell-based immunotherapies targeting solid tumors.
*past representation